Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 475 of 1463 entries
View as:

Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT01934933 Org: User:
Start: 09/24/14 End: 01/30/17 Due: 01/30/18

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

Phase: N/A Priority: Normal
NCT ID: NCT05410197 Org: User:
Start: 10/10/22 End: 08/01/25 Due: 08/01/26

Academic Performance and Refractive Error

Phase: N/A Priority: Normal
NCT ID: NCT04338880 Org: User:
Start: 09/01/16 End: 12/01/20 Due: 12/01/21

Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Phase: N/A Priority: Normal
NCT ID: NCT04062370 Org: User:
Start: 10/01/19 End: 08/31/22 Due: 08/31/23

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study

Phase: N/A Priority: Normal
NCT ID: NCT02013089 Org: User:
Start: 12/31/13 End: 12/31/17 Due: 12/31/18

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04724239 Org: User:
Start: 03/11/21 End: 12/31/23 Due: 12/31/24

Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT03529266 Org: User:
Start: 06/01/18 End: 08/22/21 Due: 08/22/22

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT06013618 Org: User:
Start: 06/19/23 End: 12/31/27 Due: 12/31/28

Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06524466 Org: User:
Start: 07/23/24 End: 12/01/26 Due: 12/01/27

CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT01533727 Org: User:
Start: 08/31/11 End: 12/31/20 Due: 12/31/21

Zhaoqing Myopia Study

Phase: N/A Priority: Normal
NCT ID: NCT04219228 Org: User:
Start: 12/14/19 End: 02/02/23 Due: 02/02/24

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06139419 Org: User:
Start: 07/25/23 End: 08/31/26 Due: 08/31/27

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Phase: N/A Priority: Normal
NCT ID: NCT06433869 Org: User:
Start: 12/14/23 End: 12/31/26 Due: 12/31/27

A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT05600491 Org: User:
Start: 11/08/15 End: 12/01/25 Due: 12/01/26

Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04959500 Org: User:
Start: 06/10/21 End: 10/31/23 Due: 10/31/24

Increased Risk of ADHD Among Children With Bilateral Congenital Cataracts

Phase: N/A Priority: Normal
NCT ID: NCT03692728 Org: User:
Start: 07/01/16 End: 12/01/16 Due: 12/01/17

MR-linac Guided Adaptive Radiotherapy for Inoperable Mediastinal Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05163509 Org: User:
Start: 10/01/21 End: 10/01/23 Due: 10/01/24

Randomized Study of Adjuvant Radiotherapy After Curative Resection of HCC With Narrow Margin (RAISE)

Phase: N/A Priority: Normal
NCT ID: NCT03732105 Org: User:
Start: 08/08/18 End: 08/11/25 Due: 08/11/26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04605575 Org: User:
Start: 05/22/20 End: 12/01/23 Due: 12/01/24

The Efficacy of Immunodetection Point Inhibitors for Advanced Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04074447 Org: User:
Start: 05/01/19 End: 05/31/21 Due: 05/31/22

CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02362165 Org: User:
Start: 04/30/15 End: 05/31/18 Due: 05/31/19

Multifocal Contact Lenses vs Bifocal Spectacles for Congenital Cataracts

Phase: N/A Priority: Normal
NCT ID: NCT03260764 Org: User:
Start: 08/20/17 End: 12/31/17 Due: 12/31/18

TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria

Phase: N/A Priority: Normal
NCT ID: NCT05883176 Org: User:
Start: 06/01/23 End: 07/01/25 Due: 07/01/26

R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT04842487 Org: User:
Start: 04/10/21 End: 12/30/23 Due: 12/30/24

The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Phase: N/A Priority: Normal
NCT ID: NCT03368651 Org: User:
Start: 01/01/16 End: 12/31/28 Due: 12/31/29